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Abstract
Introduction: Cardiac syndrome X (CSX) is characterized by anginal pain with
ECG suggestive of ischaemia and normal coronary arteries at angiography.
Pathology of CSX involves microvascular dysfunction and is possibly linked with
metabolic syndrome. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
an enzyme involved in glycolysis. The GAPDH gene is a “housekeeping” gene
and is used for normalization in quantitative gene expression assays. The aim
of the study was to evaluate GAPDH gene expression in CSX.
Material and methods: The study was performed in 35 CSX patients and 10 con  -
trol subjects. mRNA was extracted from peripheral blood mononuclears and the
mRNA was assessed by QRT-PCR.
Results: GAPDH gene expression was enhanced in CSX patients vs. controls
(93022 ±23837 copies/µg vs. 1067 ±240 copies/µg respectively; p < 0.001).
Moreover, transcriptional activity of the GAPDH gene was heterogeneous within
the CSX group.
Conclusions: GAPDH gene expression is markedly enhanced in CSX, which
reflects carbohydrate metabolism disturbances and makes the GAPDH gene
unsuitable as an endogenous control in patients with CSX.
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Introduction
Cardiac syndrome X (CSX, also referred to as microvascular angina) is
characterized by effort-induced chest pain with ECG suggestive of
ischaemia and normal coronary arteries at angiography [1]. In spite of
better and better non-invasive techniques in the diagnostics of angina,
about 20% of patients presenting with angina are still found to have 
a normal or near normal coronary angiogram.
The pathogenesis of syndrome X remains unclear. Two major
abnormalities are thought to play a crucial role: microvascular dysfunction
(with an underlying inflammatory process affecting endothelial cells) and
abnormal pain sensitivity [1-2]. Recently evidence has been gathered to
support the hypothesis that there is a link between microvascular angina
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and metabolic syndrome – a constellation of
cardiovascular risk factors (obesity, dyslipidaemia,
hypertension and glucose metabolism disturbances)
resulting mainly from hyperinsulinaemia [3].
According to the literature, including data from our
research, the pro-inflammatory state affecting
endothelium in CSX patients is also reflected by
activation of circulating inflammatory cells and
cytokines [4, 5, 6, 7].
Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) is an enzyme participating in glucose
metabolism, particularly glycolysis. The protein,
however, has been reported to possess a variety of
diverse biological functions including control of gene
expression and more [8].
The GAPDH gene is one of the constitutive and
so-called ‘housekeeping’ genes which are expressed
at all stages of the cell’s life cycle. Warrington et al.
indicated more than 500 such genes; however, only
47 of them keep the same level of transcriptional
activity all the time and may therefore be used as
an endogenous control and a standard for
normalization in quantitative gene expression
analyses [9]. Although under some conditions
GAPDH gene expression is highly inducible, it is still
one of the best characterized and therefore
commonly used for normalization of gene
expression in experiments [10].
The aim of this study was to evaluate expression
of the GAPDH gene in CSX and to determine
whether it is suitable as a normalization standard
for quantitative gene expressions analysis in these
patients.
Material and methods
Patients
The study was carried out in 35 patients aged 44-
77 (average 57 years old; M/F: 13/22) with CSX during
their symptomatic period (patients with positive
exercise test admitted to the hospital due to
recurrent chest pain in which coronary angiography
was found to be normal). Treatment in the CSX group
involved: nitrates (10 pts, 28.5%) statins (22 pts,
62.9%) ACE inhibitors (18 pts, 51.4%) and β-blockers
(27 pts, 77%). The control group consisted of 10
sexand age-matched healthy subjects (aged 39-66,
average 56 years old; M/F: 3/7).
In each patient basic laboratory tests, ECG and
echocardiography were performed. Patients with
diabetes, arterial hypertension, chronic inflam  -
matory diseases, chronic heart failure and renal
failure were excluded. Informed consent was
obtained from each patient.
Blood samples (10 mL) were collected into tubes
containing EDTA and peripheral blood mononuclear
cells (PBMC) were separated by Histopaque (Sigma,
USA) density gradient centrifugation.
RNA extraction
Total RNA was extracted from PBMC using the
phenol-chloroform method. All extracts were
treated with DNase I to avoid contamination by
genomic DNA. The RNA extracts were qualitatively
evaluated by electrophoresis in 1% agarose gel
stained with ethidium bromide, and quantitated
spectrophotometrically (Gene Quant II by Phar  -
macia).
Primers
Primers for amplification of GAPDH and β-actin
were determined using the Primer Express Version
1.0 computer program (PE Applied Biosystems,
USA), and their sequence homologies were checked
using the GenBank database. Primers sequences
were the following:
GAPDH:
5’ GAAGGTGAAGGTCGGAGTCA 3’ (forward),
5’ GAAGATGGTGATGGGATTTC 3’ (reverse),
β-actin:
5’ TCACCCACATGTGCCCATCTACGA 3’ (forward),
5’ CAGCGGAACCGCTCATTGCCAATGG 3’ (reverse).
Real-time PCR (QRT-PCR)
Quantitative reverse transcriptase polymerase
chain reaction (QRT-PCR) was performed using
QuantiTect SYBR Green RT-PCR. Cycling conditions
were as follows: RT: 60°C for 30 min; polymerase
activation: 94°C for 15 min; PCR: 94°C for 15 s and
68°C for 30 s, 40 cycles; final elongation: 72°C for
10 min. QRT-PCR specificity was confirmed
experimentally by PAA electrophoresis, amplimers’
melting temperature measurement using ABI
PRISM7000 (SYBR Green RT-PCR Kit), and sequence
analysis using ABI PRISM 377 DNA Sequencer (PE
Applied Biosystems). The obtained results were
recalculated to 1 µg of total RNA.
Statistical analysis
All values were expressed as means ± standard
error (AVG ± SEM). In order to check the normality
of the distribution, the Shapiro-Wilk test was
performed. Since the distribution was not normal
the Mann-Whitney U test was used to compare the
groups.
The investigation conforms to the principles
outlined in the Declaration of Helsinki.
Results
Results are expressed as the number of mRNA
copies of the assessed gene per 1 microgram of
total mRNA (c/µg).
We observed a tremendously higher level of
GAPDH gene expression in CSX patients vs. the
control group (93022 ±23837 copies/µg vs. 1067Arch Med Sci 5, October / 2010 711
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±240 copies/µg respectively; p < 0.001) (Figure 1). 
β-actin gene expression was not different between
the control and study group (p = NS).
Only samples that underwent RNA quality
control were subject to statistical analysis. The RNA
integrity number (RIN) for analysed samples was
6.6-8.4, which allows us to conclude that the quality
of RNA in studied samples was comparable and the
observed results are due to differences in
transcriptional activity of the GAPDH gene between
CSX and control subjects.
We did not find any correlation between studied
gene expression and any of the medications the
studied patients had been administered.
Discussion
The GAPDH gene is a widely used constitutive
gene in quantitative assays of expression of various
genes in tissues and systems. According to Barber
and coworkers, who studied GAPDH gene
expression in 72 healthy tissues, it shows small
within-tissue variation and seems to be a good
standard for normalization [10]. Under pathological
circumstances, however, some factors may cause
alterations in activity of genes that are normally
expressed at a constant level. In this study we have
demonstrated that 1) transcriptional activity of the
GAPDH gene is significantly higher in mononuclears
from CSX patients and 2) cannot therefore be 
a good endogenous control in this pathology.
As stated, PBMC from patients with syndrome X
present with increased activity and enhanced
generation of oxidative stress. According to our
previous reports [5, 6] mononuclears from CSX
patients overexpress pro-inflammatory genes, i.e.
interferon gamma receptor or kinin signalling
system. GAPDH, despite being commonly used as
a constitutive gene, has been shown to be
disturbed in various conditions. It has been proved
that inflammatory factors [11], hyperinsulinaemia
[12] and finally hypoxia [13] may enhance
transcriptional activity of GAPDH. There are also
other factors to influence GAPDH activity (glucose,
NO, superoxide) [11, 14], although their effect has
not been studied at the transcriptional level.
Increased activity of the GAPDH gene observed
in our study may be related to enhanced activation
of circulating mononuclears, the proinflammatory
state and increased oxidative stress. However, this
study was not designed to specify which
mechanism was responsible for GAPDH gene
expression. To rule out major glucose metabolism
disturbances, patients with pre-diabetes and
diabetes were excluded.
Apart from pathology of CSX itself, pharma  -
cological treatment might have had an effect on
GAPDH gene expression. As presented, treatment
in the CSX group involved statins, beta-blockers and
ACE inhibitors – groups of drugs of known anti  -
inflammatory effect and gene expression down  -
regulating potential. However, we did not observe
a correlation of GAPDH expression with any
treatment, which may have been due to the small
number of participants – a major limitation of the
study.
Apart from glycolysis, GAPDH is a protein
involved in a number of processes [9] and elevated
GAPDH expression might also reflect processes
which are not yet well evaluated. To confirm that
however, more thorough research needs to be
performed.
In conclusion, transcriptional activity of the GAPDH
gene in PBMC from patients with syndrome X is
markedly enhanced. The increased activity may be
due to an inflammatory state, may result from
prolonged hypoxia, or may reflect subclinical
glucose metabolism disturbance in CSX patients.
Moreover, such enhanced activity and heterogeneity
of GAPDH gene expression does not allow it to be
used as a standard for endogenous control in
patients with CSX.
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Figure 1. Transcriptional activity of GAPDH gene in
CSX vs. Control subjects
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